Have Patent, Will Travel: Brand Firms Can File Infringement Suits Anywhere
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal Circuit denies Mylan's bid to dismiss litigation in Delaware; PhRMA, BIO and Teva argued that brand manufacturers should be allowed to sue multiple generic manufacturers in a single forum.
You may also be interested in...
Biopharma Asks US Supreme Court Not To Limit Patent Litigation Venue
Innovators say case before court could upend ANDA litigation by preventing consolidation of cases; Genentech sees potential impact on biosimilar suits.
Biopharma Asks US Supreme Court Not To Limit Patent Litigation Venue
Innovators say case before court could upend ANDA litigation by preventing consolidation of cases; Genentech sees potential impact on biosimilar suits.
Supreme Court And Patents: What’s Not Happening
High court denies petition by Mylan to limit patent litigation venue and petition by Merck KGAA to address whether “on sale” bar to obtaining patent applies to non-public sales; Zarxio case to go to conference Friday.